Real-World Evaluation of Trastuzumab Emtansine Biosimilar in Early-Stage HER2-Positive Breast Cancer: Results from a Single-Centre retrospective Study in India Real-World outcomes of T-DM1 Biosimilar
Abstract
Background: Trastuzumab emtansine (T-DM1), an antibody–drug conjugate targeting HER2, is an established adjuvant therapy for residual invasive HER2-positive breast cancer after neoadjuvant treatment. Real-world evidence on trastuzumab emtansine biosimilars in early-stage disease is limited. This study evaluated invasive disease-free survival (IDFS) and safety outcomes with a trastuzumab emtansine biosimilar in routine practice.
Methods: This retrospective, single-centre observational study include 24 women with stage II/III HER2-positive breast cancer who received adjuvant trastuzumab emtansine biosimilar (3.6 mg/kg every 21 days) after neoadjuvant chemotherapy and surgery. The primary endpoint was IDFS; secondary endpoints were relapse patterns and treatment-emergent adverse events.
Results: Median age was 60.3 years; 83.3% were postmenopausal. At diagnosis, 20.8% had stage II and 79.2% had stage III disease. With a median follow-up of 14 months, five IDFS events occurred and no deaths were reported. Median IDFS was 14 months (95% CI: 13–15) and should be interpreted descriptively due to few events and short follow-up. Relapse occurred in 20.8%, most commonly in bone, brain, and liver. Common adverse events were thrombocytopenia (95.8%), neutropenia (79.2%), and anaemia (41.7%), predominantly grade 1–2. Left ventricular ejection fraction declined to <50% in 20.8%.
Conclusion: Adjuvant trastuzumab emtansine biosimilar use was feasible with a manageable safety profile in this single-centre real-world cohort. Efficacy findings are exploratory and require confirmation in larger prospective studies.
Full text article
References
Li YW, Dai LJ, Wu XR, Zhao S, Xu YZ, Jin X, et al. Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies. Cancer Res. 2024;84(21):3669–3683. doi:10.1158/0008-5472.CAN-24-1176.
Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. 2014;106(8):dju152. doi:10.1093/jnci/dju152.
Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, et al. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nat Commun. 2024;15:10402. doi:10.1038/s41467-024-53498-5.
Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010;28(9):963–968. doi:10.3109/07357907.2010.512598.
Erickson AW, Ghodrati F, Habbous S, Jerzak KJ, Sahgal A, Ahluwalia MS, et al. HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. Neurooncol Adv. 2020;2(1):vdaa136. doi:10.1093/noajnl/vdaa136.
Li SG, Li L. Targeted therapy in HER2-positive breast cancer. Biomed Rep. 2013;1(4):499–505. doi:10.3892/br.2013.112.
Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart MJ, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122(5):603–612. doi:10.1038/s41416-019-0635-y.
Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. doi:10.1016/j.breast.2022.08.010.
Kulothungan V, Ramamoorthy T, Sathishkumar K, Mohan R, Tomy N, Miller GJ, et al. Burden of female breast cancer in India: estimates of YLDs, YLLs, and DALYs at national and subnational levels based on the national cancer registry programme. Breast Cancer Res Treat. 2024;205(2):323–332. doi:10.1007/s10549-024-07278-5.
Singh K, Grover A, Dhanasekaran K. Unveiling the cancer epidemic in India: a glimpse into GLOBOCAN 2022 and past patterns. Lancet Reg Health Southeast Asia. 2025;34:100951. doi:10.1016/j.lansea.2025.100951
Nagarjun BR, Parikh B, Patel MN, Trivedi PJ, Patel DM. Indian data on HER2 fluorescence in situ hybridization in invasive breast cancer with immunohistochemically equivocal results as per 2018 ASCO/CAP guidelines. South Asian J Cancer. 2022;11(4):281–286. doi:10.1055/s-0042-1757758.
Baruah P, Sarma A, Bhattacharyya M, Saema P, Das BC, Sarma D, et al. Elevated FISH Her-2/neu amplification in ER positive, IHC Her-2 equivocal invasive breast cancer patients of North-East India. Asian Pac J Cancer Care. 2024;9(4):705–711. doi:10.31557/APJCC.2024.9.4.705-711.
Denkert C, Lambertini C, Fasching PA, Pogue-Geile KL, Mano MS, Untch M, et al. Biomarker data from the phase III KATHERINE study of adjuvant T-DM1 versus trastuzumab for residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. Clin Cancer Res. 2023;29(8):1569–1581. doi:10.1158/1078-0432.CCR-22-2803.
Geyer CE, Loibl S. Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy. Breast. 2025;81:104450. doi:10.1016/j.breast.2025.104450.
Conte P, Schneeweiss A, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, et al. Patient-reported outcomes from KATHERINE: a phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer. Cancer. 2020;126(13):3132–3139. doi:10.1002/cncr.32862.
Thukral DG, Thummar DV, Mehta DP, Janagama DV, Khambhati K. Drug utilization pattern of world’s first T-DM1 biosimilar (UJVIRA) for Her2+ breast cancer in first year of its availability–an Indian context. Int J Med Sci Clin Invent. 2023;10(02):6561–6568. doi:10.18535/ijmsci/v10i02.05.
Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N Engl J Med. 2025;392(3):249–257. doi:10.1056/NEJMoa2409646.
Kesireddy M, Krishnamurthy J. T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer—interpreting ATEMPT trial results from a clinical perspective. Gland Surg. 2025;14(4):785–790. doi:10.21037/gs-24-452.
Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115–126. doi:10.1016/S1470-2045(17)30716-7.
Wuerstlein R, Ellis P, Montemurro F, Antón Torres A, Delaloge S, Zhang Q, et al. Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. ESMO Open. 2022;7(5):100561. doi:10.1016/j.esmoop.2022.100561.
Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534–2542. doi:10.1200/JCO.2010.33.3179.
Zullig LL, Peppercorn JM, Schrag D, Taylor DH Jr, Lu Y, Samsa G, et al. Financial distress, use of cost-coping strategies, and adherence to prescription medication among patients with cancer. J Oncol Pract. 2013;9(6 suppl):60s–63s. doi:10.1200/JOP.2013.000262.
Mamori T, Tanioka M, Takada K, Hamano H, Tsukioki T, Takahashi Y, et al. Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness. BioDrugs. 2025 Jan;39(1):131-142. doi: 10.1007/s40259-024-00686-x.
Authors
Copyright (c) 2026 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.